Molecular optical imaging: Applications leading to the development of present day therapeutics

NeuroRx

Volumn 2, Issue 2, 2005, Pages 215-225

  Shah, Khalid ^a   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bioluminescence; Fluoresce; Gene expression; Near infrared fluorochromes; Optical imaging; Viral proteases

Indexed keywords

BIOLUMINESCENCE; CONFOCAL MICROSCOPY; FLUORESCENCE; GENE EXPRESSION; GLIOMA; INFRARED RADIATION; MOLECULAR IMAGING; OPTICAL TOMOGRAPHY; REVIEW; STEM CELL;

EID: 16344363226     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.2.215     Document Type: Article

References (58)

1. Brown EB, Campbell RB, Tsuzuki Y, Xu L, Carmeliet P, Fukumura D, Jain RK. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 7:864-868, 2001.
2. Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, Wiedenmann B, Grotzinger C. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 19:327-331, 2001.
3. Callahan R, Bogdanov A, Fischman A, Brady T, Weissleder R. Preclinical evaluation and phase 1 clinical trial of a 99mTc labeled synthetic polymer used in blood pool imaging. Am J Roentgenol 171:137-143, 1998.
4. Tung C, Bredown S, Mahmood U, Weissleder R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjugate Chem 10:892-896, 1999.
5. Weissleder R, Mahmood U. Molecular imaging. Radiology 219:316-333, 2001.
6. Yu AE, Hewitt RE, Connor EW. Novel targets for directed cancer therapy. Drugs Aging 11:229-244, 1997.
7. Weissleder R, Tung C-H, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotech 17:375-378, 1999.
8. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 60:4953-4958, 2000.
9. Davies, B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365-5369, 1993.
10. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 878:212-227, 1999.
11. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385:729, 1997.
12. Stearns ME, Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 53:878-883, 1993.
13. Moses MA, Wiederschain D, Loughlin, KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395-1399, 1998.
14. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appell K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878:236-270, 1999.
15. Rooprai HK, McCormick D. Proteases and their inhibitors in human brain tumours: a review. Anticancer Res 17:4151-4162, 1997.
16. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7:743-748, 2001.
17. Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC, Gujrati M, Rao JS. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 22:5967-5975, 2003.
18. Gondi CS, Lakka SS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Tung CH, Weissleder R, Rao JS. Adenovirus mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion and angiogenesis in gliomas. Cancer Res 64:4069-4077, 2004.
19. Reed JC. Apoptosis-based therapies. Nat Rev Drug Disc 1:111-121, 2002.
20. Thornberry N, Lazebnik Y. Caspases: enemies within. Science 281:1312-1316, 1998.
21. Bustamante J, Bersier G, Romero M, Badin RA, Boveris A. Nitric oxide production and mitochondrial dysfunction during rat thymocyte apoptosis. Arch Biochem Biophys 376:239-247, 2000.
22. Kim YM, Chung HT, Simmons RL, Billiar TR. Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem 275:10954-10961, 2000.
23. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller, DK, Molineaux, SM, Weidner JR, Aunins J. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356:768-774, 1992.
24. Messerli S, Prabhakar S, Tang Y, Shah K, Cortes M, Murthy V, Weissleder R, Breakefield XO, Tung, CH. A novel method for imaging apoptosis using a caspase-1 (ICE) near-infrared imaging probe. Neoplasia 6:95-105, 2004.
25. Schlegel RA, Williamson P. Phosphatidylserine, a death knell. Cell Death Differ 8:551-563, 2001.
26. Schellenberger EA, Bogdanov A Jr, Petrovsky A, Ntziachristos V, Weissleder R, Josephson L. Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia 5:187-192, 2003.
27. Shah K, Tung CH, Chang J, Weissleder R, Breakefield XO. In vivo imaging of HIV-1 protease activity in amplicon vector transduced gliomas. Cancer Res 64:273-278, 2004.
28. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682, 1995.
29. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818, 1997.
30. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260, 1999.
31. Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 64:3236-3242, 2004.
32. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 94:271-305, 1999.
33. Jaffer FA, Tung CH, Wykzykowska JJ, Ho NH, Houng AK, Reed GL, Weissleder R. Molecular imaging of factor XIIIa activity in thrombosis using a novel, NIRF contrast agent that covalently links to thrombi. Circulation 110:170-176, 2004.
34. Contag CH, Ross BD. It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging 16:378-387, 2002.
35. Rice BW, Cable MD, Nelson MB. In vivo imaging of light-emitting probes. J Biomed Opt 6:432-440, 2001.
36. Honigman A, Zeira E, Ohana P, Abramovitz R, Tavor E, Bar I, Zilberman Y, Rabinovsky R, Gazit D, Joseph A, Panel A, Shai E, Palmon A, Laster M, Galun E. Imaging transgene expression in live animals. Mol Ther 4:239-249, 2001.
37. Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2:41-52, 2000.
38. Wu JC, Sundaresan G, Iyer M, Gambhir SS. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther 4:297-306, 2001.
39. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 96:12044-12049, 1999.
40. Contag CH, Contag PR, Mullins JI, Spilman SD, Stevenson DK, Benaron DA. Photonic detection of bacterial pathogens in living hosts. Mol Microbiol 18:593-603, 1995.
41. Shah K, Tang Y, Breakefield XO, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 22:6865-6872, 2003.
42. Ntziachristos V, Kreis R, Boesch C, Quistorff B. Diploar resonance frequency shifts in 1H MR spectra of skeletal muscle: confirmation in rats at 4.7 T in vivo and observation of changes postmortem. Magn Reson Med 38:33-39, 1997.
43. Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Ther 11:1175-1187, 2004.
44. Rehemtulla A, Hall DE, Stegman LD, Prasad U, Chen G, Bhojani MS, Chenevert TL, Ross BD. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging 1:43-55, 2002.
45. Soling A, Theiss C, Jungmichel S, Rainov NG. A dual function protein of HSV-1 TK and Flue for non invasive in vivo imaging of gene therapy in malignant gliomas. Genet Vaccines Ther 2:7, 2004.
46. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 99:377-382, 2002.
47. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, Rehemtulla A. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 99:16551-16555, 2002.
48. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield X, Snyder EY. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97:12846-12851, 2000.
49. Ourednik J, Ourednik V, Lynch WP, Schachner M, Snyder EY. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 20:1103-1110, 2002.
50. Snyder EY, Deitcher DL, Walsh C, Arnold-Aldea S, Hartwieg EA, Cepko CL. Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell 68:33-51, 1992.
51. Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY Breakefield XO. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 1:347-357, 2000.
52. Tang Y, Shah K, Messerli SM, Snyder E, Breakefield XO, Weissleder R. In vivo tracking of neuronal progenitor cell migration to glioblastomas. Hum Gene Ther 14:1247-1254, 2003.
53. Stiles CD. Cancer of the central nervous system. Review of an AACR special conference in cancer research with the joint section on tumors of the AANS/CNS (San Diego, CA, June 7-11, 1997). Biochim Biophys Acta 1377:R1-R10, 1998.
54. Shah K, Bureau E, Kim D, Yang K, Tang Y, Weissleder R, Breakefield XO. Glioma therapy using TRAIL-secreting NPCs with dual imaging of NPC migration and tumor regression in vivo. Ann Neurol 57:34-41, 2005.
55. Brooks DJ. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2:226-236, 2005.
56. Devous MD. Single-photon emission computed tomography in neurotherapeutics. NeuroRx 2:237-239, 2005.
57. Bammer R, Skare S, Newbould R, Liu C, Thijs V, Ropele S, Clayton DB, Krueger G, Moseley ME, Glover GH. Foundations of advanced magnetic resonance imaging. NeuroRx 2:167-196, 2005.
58. Lin A, Ross, BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision-making. NeuroRx 2:197-214, 2005.